H.R. 6094 · 118th Congress

Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act

Introduced on Oct 26, 2023 by Doris O. Matsui (D-CA-7). 26 cosponsors, 8 of them from another party. Latest action (Dec 17, 2024): Referred to the Subcommittee on Health.

Stage
Introduced
Introduced
Oct 26, 2023
Cosponsors
26
8 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition, and for other purposes.

Subjects

  • Health care costs and insurance
  • Health care coverage and access
  • Medicaid
  • Medicare
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Doris O. MatsuiD-CA-7Sponsor

Democrats · 18

Republicans · 8

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Oct 26, 2023Introduced in House
  2. Oct 26, 2023Introduced in House
  3. Oct 26, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Oct 26, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  5. Nov 3, 2023 · HouseReferred to the Subcommittee on Health.
  6. Dec 17, 2024 · HouseReferred to the Subcommittee on Health.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. ACADIA PHARMACEUTICALS5 reports
    $1.7M reported (all issues)
  2. EVERYLIFE FOUNDATION FOR RARE DISEASES5 reports
    $140K reported (all issues)
  3. BIOMARIN PHARMACEUTICAL INC.4 reports
    $1.4M reported (all issues)
  4. Blue Cross and Blue Shield Association4 reports
    $7M reported (all issues)
  5. Cleveland Clinic Foundation4 reports
    Federal contractor: THE CLEVELAND CLINIC FOUNDATION$1.1M in contracts, FY2026AI match · 100%
  6. HARMONY BIOSCIENCES, LLC4 reports
    $600K reported (all issues)Federal contractor: HARMONY BIOSCIENCES LLC$614.4K in contracts, FY2026AI match · 100%
  7. Blue Cross and Blue Shield of Florida, Inc.3 reports
    $600K reported (all issues)
  8. GUIDEWELL MUTUAL HOLDING CORPORATION3 reports
    $40K reported (all issues)
  9. National Hemophilia Foundation3 reports
    $150K reported (all issues)
  10. BCBSM, Inc.2 reports
    $62K reported (all issues)
  11. BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.2 reports
    $15K reported (all issues)
  12. BLUE CROSS BLUE SHIELD OF MICHIGAN1 report
    $269.1K reported (all issues)
  13. Fulcrum Therapeutics1 report
    $60K reported (all issues)
  14. National Bleeding Disorder Foundation (fka National Hemophilia Foundation)1 report
    $50K reported (all issues)

Reports filed in 2023, 2024, 2025.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.